文献速递甲状腺疾病

BRAFV600E突变甲状腺癌患者接受BRAF抑制剂治疗后获得性继发RAS突变

Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors.
PubMed 文献 · Thyroid · 2020-05-07

本文描述4例接受选择性BRAF抑制剂治疗的甲状腺癌患者,在疾病进展时于进展病灶或液体活检中检出BRAFV600E之外的RAS突变:患者1和3获得KRASG12V,患者2在进展淋巴结获得NRASQ61K,患者4在影像学进展时液体活检获得NRASG13D。作者认为,与黑色素瘤经验相似,RAS突变的出现似乎是甲状腺癌对BRAF抑制剂耐药的机制。

要点

  • 4例BRAFV600E突变甲状腺癌患者接受选择性BRAF抑制剂治疗后进展。
  • 进展时检出获得性RAS突变:KRASG12V、NRASQ61K、NRASG13D。
  • 作者认为RAS突变出现似乎是甲状腺癌BRAF抑制剂耐药的机制。

核心结论

  • 与黑色素瘤经验相似,RAS突变的出现似乎是甲状腺癌对BRAF抑制剂耐药的机制。

研究设计与样本

  • 本文描述4例接受选择性BRAF抑制剂治疗的甲状腺癌患者,在进展时发生BRAFV600E之外的RAS突变。

主要发现

  • 患者1和3在进展肿瘤中获得KRASG12V突变。
  • 患者2在进展淋巴结中获得NRASQ61K突变。
  • 患者4在影像学疾病进展时进行的液体活检中获得NRASG13D突变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The BRAFV600E mutation is the most common driver mutation in papillary thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered actionable and, for BRAFV600E-mutated ATC, a BRAF inhibitor (dabrafenib) in combination with an MEK inhibitor (trametinib) is FDA approved. BRAF inhibitors have also shown efficacy in BRAFV600E-mutated PTC. However, as with all targeted therapies, resistance to these drugs eventually develops. It is essential that we understand the mechanisms of resistance to the BRAF inhibitors in thyroid cancer to develop future strategies to effectively treat these patients and improve survival. Patients: Herein, we describe four patients with thyroid cancer treated with selective BRAF inhibitors, who developed a RAS mutation in addition to the BRAFV600E mutation at progression. Results: Patients 1 and 3 acquired a KRASG12V mutation in the progressive tumor, patient 2 acquired a NRASQ61K mutation in a progressive lymph node, and patient 4 acquired NRASG13D mutation on liquid biopsy performed at the time of radiographic disease progression. Conclusion: Similar to the melanoma experience, the emergence of RAS mutations appears to act as a mechanism of resistance to BRAF inhibitors in thyroid cancers.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Cabanillas ME, Dadu R, Iyer P, et al. Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid. 2020. PMID: 32216548. doi:10.1089/thy.2019.0514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。